Clinical trials for Stomach and esophageal cancer

163 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Early Access Stomach and esophageal cancer

Accès précoce post-AMM– KEYTRUDA (Pembrolizumab)

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive

1 recruiting site

Merck Sharp & Dohme LLC

Early Access Stomach and esophageal cancer

Accès précoce post-AMM - VYLOY (Zolbetuximab)

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 PDL1 Negative (< 1%) None Systemic Treatment-Naive

HER2

1 recruiting site

Astellas Pharma Développement mondial, Inc.

Phase 3 Pancreas cancer Stomach and esophageal cancer #NCT06784752 #2024-518325-15-00

[NETTER-3] Étude visant à évaluer l'efficacité et l'innocuité du [177Lu]Lu-DOTA-TATE chez les patients atteints de TNE-GEP avancé de grade 1 et de grade 2

Stomach Neuroendocrine tumor Locally Advanced Metastatic None Systemic Treatment-Naive SSTR Positive

5 recruiting sites

Novartis

Phase 3 Pancreas cancer Stomach and esophageal cancer #NCT05477576 #2023-509334-19-00

[ACTION-1] Étude de RYZ101 comparé au traitement standard chez des patients atteints de tumeur neuroendocrine entéro-gastro-pancréatique bien différencié SSTR+ inopérable ayant progressé après un traitement par 177Lu-SSA

Stomach Neuroendocrine tumor Locally Advanced Metastatic 1 Somatostatin analogs SSTR Positive

Systemic Treatment-Naive

2 recruiting sites

RayzeBio, Inc

Phase 3 Stomach and esophageal cancer #NCT06731478 #2024-513122-27-00

[Destiny-Gastric05] Étude du TRASTUZUMAB DERUXTECAN, de la CHIMIOTHERAPIE, du PEMBROLIZUMAB et du TRASTUZUMAB dans le traitement du cancer de l'estomac ou de la jonction gastro-œsophagienne métastatique HER2-positif en première intention

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 None Systemic Treatment-Naive

Targeted therapy Targeted therapy

14 recruiting sites

Daiichi Sankyo

Phase 3 Stomach and esophageal cancer #NCT06764875 #2024-512583-57-00

[ARTEMIDE-Gastric01] Étude de phase III sur le RILVEGOSTOMIG en association avec la FLUOROPYRIMIDINEet le TRASTUZUMAB DERUXTECAN comme traitement de première intention du cancer gastrique HER2-positif

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic HER2 None Systemic Treatment-Naive CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)

6 recruiting sites

AstraZeneca

Phase 3 Stomach and esophageal cancer #NCT06346197 #2023-506291-28-00

[CIME] Association d'inhibiteurs de points de contrôle immunitaire dans les adénocarcinomes œsogastriques MSI/dMMR localement avancés ou métastatiques

Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic MSI/dMMR None Systemic Treatment-Naive CPS Positive (5 <= X < 10) CPS Positive (X >= 10)

HER2 Immunotherapy Immunotherapy

6 recruiting sites

Centre Léon Bérard

Phase 3 Stomach and esophageal cancer #NCT07270991 #2025-522395-92-00

[FRUQUITAS] Trifluridine/Tipiracil + Fruquintinib versus Trifluridine/Tipiracil seul pour l'adénocarcinome œsogastrique métastatique

Stomach Oesogastric junction Esophagus Adenocarcinoma Metastatic 2 3 or more Chemotherapy

Systemic Treatment-Naive

11 recruiting sites

Fédération Francophone de Cancérologie Digestive

Phase 3 Stomach and esophageal cancer #NCT06644781 #2023-509630-19-00

Étude de l'ifinatamab deruxtecan chez des sujets atteints d'un carcinome épidermoïde de l'œsophage (ESCC) avancé ou métastatique prétraité

Esophagus Squamous cell carcinoma Locally Advanced Metastatic 1 Immunotherapy Chemotherapy

Systemic Treatment-Naive

10 recruiting sites

Daiichi Sankyo

Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00

[LUCERNA] Étude du ZOLBETUXIMAB associé au PEMBROLIZUMAB et à la chimiothérapie chez les adultes atteints d'un cancer gastrique

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 None Systemic Treatment-Naive CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)

HER2 Immunotherapy Chemotherapy

18 recruiting sites

Astellas Pharma Développement mondial, Inc.